Latest Regulatory News

Tamawood Limited reports a modest profit increase for FY25 alongside the retirement of long-serving Chairman Robert Lynch. Early FY26 sales surge 39%, but a Work in Progress audit prompts a trading blackout.

Veganic SKN Ltd has launched legal action against Cancer Council Australia over alleged misleading claims about chemical UV filters in sunscreens, coinciding with recent product recalls and the company’s ambitious growth plans for 2026.

Biotron Limited’s lead HBV drug BIT-HBV001 demonstrates superior antiviral activity and synergy with the current standard treatment Tenofovir in preclinical models, advancing hopes for a more effective Hepatitis B therapy.

Smart Parking Limited has delivered record FY25 results, driven by strong organic growth and strategic acquisitions including its entry into the US market with Peak Parking. The company is targeting 3,000 ANPR sites globally by 2028, leveraging proprietary AI technology and a capital-light model.

Besra Gold Inc. reported a $3.47 million loss for Q1 2026, weighed down by finance costs tied to a major gold purchase agreement. Despite asset impairments and net liabilities, management remains cautiously optimistic about ongoing funding and project development.

PYC Therapeutics reports sustained vision improvements in patients with Retinitis Pigmentosa type 11 treated with VP-001, showing promising safety and efficacy up to 18 months. The company plans to engage the FDA in early 2026 to finalize pivotal trial design.

Bio-Gene Technology’s natural insecticide Qcide® has earned organic listing status from the US Organic Materials Review Institute, marking a pivotal step for its entry into the organic pest control market.

Synlait Milk Limited has temporarily expanded its banking facilities by NZ$50 million to manage ongoing cost impacts from earlier manufacturing challenges, while preparing to reduce debt through a major asset sale.

The Supreme Court of Western Australia has approved the share and option schemes for Capricorn Metals’ acquisition of Warriedar Resources, setting the stage for a significant consolidation in the gold exploration sector.

Sequoia Financial Group’s subsidiary InterPrac Financial Planning faces ASIC civil penalty proceedings over past investment advice but plans a robust defence.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.

Island Pharmaceuticals will host a webinar to discuss the FDA's feedback on the clinical development and regulatory approval of its antiviral drug Galidesivir, including key considerations under the FDA's Animal Rule and Priority Review Voucher eligibility.